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The intestinal barrier plays an important role in the defense against infections, and nutritional, endocrine,
and immune functions. The gut microbiota playing important role in development of the gastrointestinal
tract can impact intestinal permeability and immunity during early life, but data concerning this problem
are scare.
Methods
We analyzed the microbiota in fecal samples (101 samples in total) collected longitudinally over 24
months from 21 newborns to investigate whether the markers of small intestinal paracellular permeability
(zonulin) and immune system development (calprotectin) are linked to the gut microbiota. The results
were validated using data from an independent cohort that included the calprotectin and gut microbiota
in children during the  rst year of life.
Results
Zonulin levels tended to increase for up to 6 months after childbirth and stabilize thereafter remaining at
a high level while calprotectin concentration was high after chilbirth and begun to decline from 6 months
of life. The gut microbiota composition and the related metabolic potentials changed during the  rst two
years of life and were correlated with zonulin and calprotectin levels. Feacal calprotectin correlated
inversely with alpha diversity (Shannon index, r =-0.30, FDR P (Q)=0.039). It also correlated with seven
taxa; i.a. negatively with Ruminococccaceae (r=-0.34, Q=0.046), and Clostridiales (r=-0.34, Q=0.048) and
positively with Stapylococcus (r=0.38, Q=0.023) and Staphylococcaceae (r=0.35, Q=0.04), whereas
zonulin correlated with 19 taxa; i.a. with Bacillales (r=-0.52, Q=0.0004), Clostridiales (r=0.48, Q=0.001)
and the Ruminococcus (torques group) (r=0.40, Q=0.026). When time intevals were considered only
changes in abundance of the Ruminococcus (torques group) were associcated with changes in
calprotectin (β=2.94, SE=0.8, Q=0.015). The dynamics of stool calprotectin was negatively associated
with changes in two MetaCyc pathways: pyruvate fermentation to butanoate (β=-4.54, SE=1.08, Q=0.028)
and Clostridium acetobutylicum fermentation (β=-4.48, SE=1.16, Q=0.026).
Conclusions
The small intestinal paracellular permeability, immune system-related markers and gut microbiota
change dynamically during the  rst two years of life. The Ruminococcus (torques group) seems to be
especially involved in controlling paracellular permeability. Staphylococcus, Staphylococcaceae,
Ruminococcaceae, and Clostridiales, may be potential biomarkers of the immune system. Despite




The intestinal barrier plays important role in the defense against infections, apart from its essential
nutritional, endocrine, and immune functions.[1] Multiple factors impact intestinal permeability in infants,
including gestational age, mode of delivery and feeding, and various diseases.[2] Increased gut barrier
permeability allows the optimal nutrient uptake and leads to increased immune tolerance[3]; on the other
hand, increased permeability to foreign antigens, including intestinal bacteria, might result in
in ammation and systemic hypersensitivity.[3, 4] The gut barrier of a newborn is highly permeable;
importantly, the permeability decreases during a process known as “gut closure”.[5] The exact time of this
process in humans, regulated by growth factors, hormones and breast milk is unknown but has been
proposed to take place around 22nd week of life.[6] It could also be hypothesized that gut microbiota
may be involved in this process.[6, 7] Of note, gut permeability can be assessed via the analysis of the
absorption of various substances[8], as well as via the measurement of blood and stool markers,
including zonulin and calprotectin.[9]
Zonulin (ZON), an analog of the cholera comma toxin (ZOT, zonula occludens toxin) [10, 11] shown to
regulate paracellular transport within the small bowel.[12–14] This protein is synthesized in the liver and
epithelial cells of the intestine and is a component of multi-protein membrane complexes (claudin-
occludin-guanylate kinase-like proteins ZO-1, ZO-2, and ZO-3) forming tight junctions (TJ).[15] In fact,
zonulin regulates the tightness of TJ, which is an important part of the proper function of the intestinal
barrier.[16] Increased zonulin concentrations correlate positively with small intestinal permeability[17], a
phenomenon discovered in the context of in ammatory and autoimmune disease[18–21], and could be
considered as a biomarker for systemic in ammation.[22]
Human calprotectin is a 24 kDa dimer formed by the protein monomers S100A8 (10,835 Da) and S100A9
(13,242 Da), and makes up to 60% of the soluble proteins in the cytosol of human neutrophils.[23, 24]
The sources of calprotectin in newborns are breast milk and resident and non-resident myeloid cells.[25]
In fact, fecal calprotectin is used in older children and adults as a marker for in ammatory bowel
diseases; there is a body of evidence correlating calprotectin with in ammatory bowel diseases, cow-milk
allergy, atopic disease and other gastrointestinal disorders.[26] Of note, calprotectin has the potential to
be used as an indirect marker of gut permeability.[27] However, its role as a marker of in ammation was
not con rmed in neonates.[25]
In our previous study[28] we found that some maternal-fetal factors are associated with increased
concentration of fecal calprotectin and zonulin in children during the  rst two years of life. Additionally,
we found that after birth, zonulin levels increased up until 12 months of age, remaining high thereafter,
while calprotectin levels decreased until six months of age, stabilizing thereafter.[29] Of note, in this
previous study, we did not assess the fecal microbiota, which was a signi cant limitation; we were not
able to trace the relationships between the fecal microbiome and the concentrations of the
abovementioned stool markers. Therefore, in this study, we decided to analyze the microbiota in faecal
samples collected longitudinally over 24 months from 21 subjects to test the hypothesis that small
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intestinal barrier permeability is linked to the gut microbiota. Moreover, we validated the observed results
via comparison with the data obtained in the study by Willers et al. (Hannover Medical School - HMS
cohort) who measured the relationship between calprotectin and gut microbiota in children during the
 rst year of life.[25]
Methods
Subjects
The present observational prospective cohort study continues research efforts in the context of intestinal
barrier function in a cohort of Polish newborns, described in detail in previous publications[28, 29].
Twenty four healthy full-term newborns at the Department of Obstetrics, Gynecology and Neonatology,
the Pomeranian Medical University/Independent Public Clinical Hospital No. 2 in Szczecin (PMU cohort)
were initially recruited to this study. Longitudinal sampling was performed for over 24 months. Three
newborns were excluded due to an inadequate number of samples. In total, 21 newborns (101 samples in
total) were included in the study, with at least four longitudinal stool samples available (the sample
availability matrix is provided in Supplementary Fig. 1). Samples were taken at the following points in
time - meconium (P1, n = 8), 7 days (P2, n = 20), 1 month (P3, n = 19), 6 months (P4, n = 20), 12 months
(P5, n = 21) and 24 months (P6, n = 13) (Supplementary Fig. 2) after birth. The study was conducted
using the results obtained for the time points P2-P6. The measured markers and the meconium
microbiota composition (P1) re ect the perinatal period. Therefore the values obtained at this time point
were used instead to validate the microbiota analysis (the meconium microbiota is expected to be clearly
distinguishable from the microbiota obtained at other time points). The participants’ characteristics are
shown in Table 1.















4/4 9/11 10/9 9/11 10/11 8/5
Mode of delivery (C/V) 5/3 11/9 11/8 12/8 12/9 6/7






































Note: C- Cesarean section, V - vaginal delivery, N - natural, F- formula; P1 - meconium, P2 - 7th day, P3 - 1st
month, P4 - 6th month, P5 - 12th month, P6 - 24th month
All included newborns were exclusively breastfed during the  rst week of life. The children were healthy
and did not take antibiotics at the time the samples were collected. For validation, we used independent
Illumina MiSeq 16S rRNA data of the same hypervariable region (V3-V4) derived from 227 stool samples
of healthy term children enrolled in the HMS cohort. They were tested at seven time points (1, 2, 10, 30,
90, 180 and 360 days of age). For the sake of compatibility with the PMU cohort,  ve time points were
selected: 1 day (P1, n = 43), 10 days (P2, n = 42), 30 days (P3, n = 47), 180 days (P4, n = 43) and 360 days
(P5, n = 52) of age.
Determination of the fecal zonulin and calprotectin content
The concentrations of zonulin and calprotectin in the fecal samples were measured as previously
described.[28, 29].
Sample collection, DNA extraction and sequencing
Stool samples were collected from diapers using a standardized biological material collection kit (Stool
Sample Application System (SAS); Immundiagnostik, Bensheim, Germany). The samples were collected
by previously trained hospital staff or by the parents according to an established procedure and stored in
a refrigerator (for a maximum of eight hours) before transport. Transport to the laboratory took no longer
than 60 min, at 6–8°C. The stool samples were then frozen at − 20°C until metagenomic analyses were
conducted. Microbiome DNA extraction was performed using the Genomic Mini AX Bacteria + Spin and
Genomic Mini AX Soil Spin kits (A&A Biotechnology, Gdynia, Poland) following the manufacturer’s
protocol. DNA concentrations was determined by  uorometry (DeNovix DS-11 FX + 
Spectrophotometer/Fluorometer, Wilmington, DE, USA). Samples were subsequently stored at -20°C.
Metagenomic libraries of the V3-V4 hypervariable region of the 16S rRNA gene were constructed and
further sequenced on the MiSeq platform (paired-end 2x250 bp) using V2 chemistry from Illumina
(Illumina, San Diego, CA, USA). Next generation sequencing (NGS) was performed by Genomed S.A.,
Warsaw, Poland.
For validation, we used the independent Illumina MiSeq 16S rRNA data of the same hypervariable region
(V3-V4) derived from the 227 stool samples of healthy term children enrolled in the HMS cohort.
16S sequencing sample processing
The sequences were processed using LotuS 1.62.[30] LotuS clusters operational taxonomic units and
generates taxonomic-level abundances tables. UPARSE de novo sequence clustering removed chimeric
OTUs with 1470 OTUs (PMU cohort) and 923 OTUs (HMS cohort) remaining. OTU seed sequences were
classi ed by BLAST lower ancestor comparison to SILVA (1.32). The Rarefaction Toolkit (RTK) was used
to normalize the abundances on all taxonomic levels.[31] Two samples were removed due to their low
number of bacterial reads from the PMU cohort (read counts of 246 and 134), resulting in a  nal
rarefaction depth of 1117 16S reads, yielding a count of 594 genera resolved at this sequencing depth
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and the  nal sample size of 101 was obtained. Moreover, 108 samples were removed due to their low
number of bacterial reads from the HMS cohort (read count less than 1000), resulting in a rarefaction
depth of 1000 16S reads, yielding 484 genera and the  nal sample size of 227.
The alpha diversity (Shannon, Simpson, Chao1, Evenness) was computed using RTK taking the genus
median alpha diversity over ten rarefaction cycles. The beta diversity was calculated on a rare ed genus-
level abundance table using the Bray-Curtis dissimilarity metrics and visualized as principal coordinate
analysis (PCoA). Taxa that were present in less than 20% (PMU cohort) and 10% (HMS cohort; a lower
taxa prevalence was used to allow the comparison) of samples were removed.
To predict the metabolic pro le of gut microbiota, we used the PICRUSt2 tool.[32] The prediction of
MetaCyc metabolic pathways was conducted on the non-rare ed OTU abundance table from which rare
OTUs (present in less than 20% of samples with a minimum count of 3) were removed. In order to
address the issue of compositional data, the taxa and predicted MetaCyc pathway abundances (not
rare ed but  ltered to match the rare ed data) were transformed by generating 128 Monte Carlo
instances of the Dirichlet distribution for each gut sample, followed by center-log transformation of each
instance.[33] Analyses were performed for each instance separately and the results were then averaged
over 128 instances.
Statistical analysis
Changes over time in the context of permeability biomarkers (zonulin and calprotectin), the gut alpha
diversity indices, gut composition principal coordinate scores, or gut taxa and pathway abundances were
analyzed using mixed-effects models. Time points (P) were treated as the  xed effect and the newborn
IDs as the random effect, accounting for repeated sampling of the same individual. The signi cance of
the time point variable was tested via comparison of the likelihoods of the two nested models (likelihood
ratio test, LRT): without (null model) and with (full model) the  xed factor in question. Pairwise
comparisons between timepoints were performed using the emmeans package[34] and the Benjamini-
Hochberg procedure for the control of the false discovery rate (FDR). In the models with biomarkers
(which were rank-transformed), taxa and metabolic pathways, the mode of delivery and breastfeeding
time were also included as additional covariates and thus controlled for. The LRT p-values for taxa and
metabolic pathways were FDR-adjusted as above.
The gut microbial diversity, composition and metabolic pathways were analyzed with respect to zonulin
and calprotectin biomarkers using a repeated measures correlation method.[35] The repeated-measures
correlation (an equivalent to the linear mixed-effects model with random intercept) was used to assess
the association between the levels of the biomarkers and the alpha diversity, PCoA scores, taxa and
metabolic pathway abundance, accounting for repeated measures for each participant.
In addition, an association betwen the differences (changes) among all time points were associated
using linear mixed-effect models with random intercepts (newborn ID as a random factor). The extent of
the biomarker change was de ned as the dependent variable (DV). Then, the time period/interval - a
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categorical variable with ten levels indicating all possible differences (e.g. P2-P3, P2-P4, etc.) between the
 ve time points (P2, P3, P4, P5 and P6, PMU cohort) or four time points (P2, P3, P4, P5, HMS cohort)] and
either beta-diversity (Bray-Curtis intersample composition distance) or univariate metrics of changes in
microbiota composition or metabolic pathway abundance (between corresponding time points) were
de ned as  xed effects. To investigate the connection between the change in the overall compositional
pro le and the change in the levels of biomarkers, we took the within-subject Bray-Curtis distances
(computed at the genus level using rare ed abundances). Fine-grained analysis was performed using
changes in the taxonomic composition (from genus to phylum level) and metabolic pathways which were
computed using the center-log transformed Monte Carlo instances of the Dirichlet distribution. Two sets
of likelihood ratio tests were performed (with mode of delivery and breastfeeding time as covariates). In
the  rst LRT, a signi cance of the Bray-Curtis distance or change in abundance was assessed under the
assumption of no interaction between the  xed factors (the common slope model). The second LRT was
used to determine whether the interaction was statistically signi cant. In case of a signi cant interaction
effect, the emmeans package was used (emtrends function) to estimate the individual slopes over levels
of the time period/interval. The p-values for the slopes (coe cients) were determined and adjusted for
multiple testing to control for the FDR. The analysis was performed using R (https://cran-r.ptoject.org).
Data was manipulated using Perl. A signi cance level of 5% was used for raw and FDR adjusted p-
values.
Results
Stool levels of zonulin and calprotectin increase and decrease over time, respectively
Both stool zonulin and calprotectin concentrations changed signi cantly over time in the cohort (Fig. 1,
LRT, df = 4, P = 2.6e-05, and df = 4, P = 10.0e-05, respectively; adjusted for the mode of delivery and
breastfeeding duration).
Zonulin levels at P2 (7 days after birth) and P3 (1 month after birth) were signi cantly lower than those at
the time points P4, P5, and P6. However, from P4 to P6 (6th and 24th months of life), no signi cant
differences were observed (between any two time points, non-consecutive or consecutive). Thus, zonulin
levels tended to increase for up to 6 months after birth (P4) and stabilize thereafter (Fig. 1A). In contrast
to zonulin, calprotectin levels did not differ signi cantly between any consecutive time points (Fig. 1B).
Moreover, up to and including P4, none of the differences in calprotectin levels between any two time
points (non-consecutive or consecutive) were signi cant. However, the calprotectin levels at P5 were
signi cantly lower than those at P2, P3; additionally, the calprotectin levels at P6 were also signi cantly
lower than those at P2, P3, and P4 (Fig. 1B). Overall, these results suggest that between about six and
twelve months of age, the zonulin levels stabilize remaining at a high level, while calprotectin
concentration begins to decline. Importantly, the analysis of the HMS validation cohort (Supplementary
Fig. 3) con rmed the declining trend of calprotectin from P3 onwards; of note, a signi cant difference
was determined between the  rst and sixth months of life, which altogether strongly highlights the sixth
month of life as an important time point concerning changes of analyzed markers after childbirth.
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Interestingly, despite the observed opposite trends in the context of stool zonulin and calprotectin levels,
the two markers did not appear to correlate with each other (LRT; common slope model: df = 1, P = 0.776,
β = 0.03, SE = 0.09; interaction model: df = 9, P = 0.419, Fig. 1C).
Gut microbiota diversity, taxonomy and metabolic pathways
during the  rst two years of life
Gut microbiota diversity
The alpha diversity was measured using the Shannon index (Fig. 2A); sample diversity differed
signi cantly between time points (LRT, df = 5, P = 6.61e-09). Speci cally, P2’s alpha diversity was
signi cantly lower than in P4, P5 and P6, whereas P3’s alpha diversity was signi cantly lower than in P5
and P6. We have validated those results by comparing diversity in stool samples with that in meconium
in the two cohorts of children (PMU and HMS). In the PMU, the Shannon indexes in P2 (Q < 0.0001), P3 (Q 
= 0.0001), P4 (Q = 0.004) were signi cantly lower than that in P1; on the other hand, the Shannon indexes
in P5 (Q = 0.109) and P6 (Q = 0.201) did not differ signi cantly from that. Altogether, these results indicate
that the meconium samples have the highest alpha diversity; interestingly, our data suggest that the
newborn’s gut microbiota diversity  rst decreases but then is restored over time (Fig. 2A). Importantly, a
similar pattern was evident in the HMS cohort data (Supplementary Fig. 4A), except for a clear
discrepancy between the  rst samples’ diversity (in the HMS cohort, the lowest diversity was detected at
day 1, giving rise to a monotonically increasing trend in this cohort). This can occur if “high diversity”
meconium samples (bacteria derived from the mother and environment following birth [36] are combined
with early newborns’ stool “low diversity” samples (in the PMU cohort, only meconium stool samples were
analyzed while in the HMS cohort also the  rst stool samples were analyzed in some cases).
The ordination of samples in a two-dimensional space performed as per a principal coordinate (PCo)
analysis on Bray-Curtis distances dissimilarity based on genus abundance showed a sequential change
in the gut microbial communities (Fig. 2B), especially along the PCo2 axis, where the transition of the gut
microbial composition was smooth and gradual so that the differences in the PCo2 scores were
signi cant only between more distant time points, i.e. P2-P4/P5/P6, P3-P5/P6 and P4-P6 (Fig. 2D). The
meconium community composition was markedly dissimilar from those in later samples in both cohorts.
This was especially evident along the PCo1 axis (Fig. 2C, Supplementary Fig. 4C): in the PMU, the PCo1
scores were signi cantly different among all time points except for P4. Altogether, these results align with
previous  ndings regarding taxonomic composition of the meconium and fecal samples [25, 36],
validating the microbial analysis methods used.
Gut microbiota composition and functional pro les during the  rst two years of life
The bacterial taxonomic and functional (PICRUSt2-predicted) development during the  rst two years of
life was analyzed using linear mixed-effect modeling of the centered log-ratio transformed 128 Monte
Carlo instances of the Dirichlet distribution in samples from 7th day (P2) to the 24th month (P6) of age.
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Twenty-seven out of 47 evaluated genera that met the prevalence criterion either increased or decreased
signi cantly during that period (Fig. 3A). Of note, the changes in the Staphylococcus and Ruminococcus
(torques group) abundance were approximately monotonic throughout that time (Fig. 3B). In general, the
abundance tended to stabilize around one year of life (P5) with only mild alterations thereafter (see the
column P5P6 in Fig. 3A). Interestingly, except for Staphylococcus, the abundance was relatively constant
until the end of the  rst month of life (P3, see the P2P3 column in Fig. 3A). Longitudinal changes in the
bacterial composition at higher taxonomic ranks are shown in Supplementary Fig. 5.
Remarkably,  fteen genera whose abundance changed signi cantly over time overlapped between the
PUM and HMS cohorts (Fig. 3A, Supplementary Fig. 6). This overlap accounted for 60.0% and 51.7% of
the signi cantly affected taxa in the PMU (P2 to P6) and HMS (P2 to P5), respectively. Moreover, for
overlapping genera, the patterns of temporal changes in abundance were similar (either decreasing or
increasing); the degree of changes between time points also exhibited a similar pattern (i.e. P2P3, P2P4,
P3P4).
To infer the functional pro le of the microbial communities, we used the PICRUSt2 software. We
identi ed 110 MetaCyc pathways (out of 332 predicted) in the PMU cohort that were signi cantly
associated with time. In general, almost all pathways (except PWY-7332) did not change signi cantly in
abundance after P5, and the majority of pathways stabilized even earlier at around the 6th month of age
(P4). In the HMS cohort, the analysis of predicted MetaCyc pathways revealed 223 pathways (out of 290
predicted) whose abundance changed signi cantly over the observation period (P2 to P5). Importantly,
there were 76 pathways whose abundance changed over time in the two cohorts (Supplementary Fig. 7),
accounting for 75.2% and 34.1% of the signi cant pathways in the PMU and HMS cohorts, respectively.
Remarkably, there was a very high degree of consistency between the cohorts regarding the direction and
dynamics of the pathways’ abundance.
Gut microbiota diversity, composition and metabolic
pathways concerning the stool levels of zonulin and
calprotectin
Next, we focused on the relationships between microbiota diversity, composition, predicted function and
permeability/in ammatory markers. In a  rst step, we assessed whether the time intervals with
signi cant changes in bacterial diversity, abundance and predicted metabolic functions overlapped with
the time intervals associated with an increase in zonulin (i.e. P2-P4/P5/P6, P3-P4/P5/P6) and decrease
in calprotectin (i.e. P2-P5/P6, P3-P5/P6, P4-P6). Then, in a second step, we used a statistical technique
(repeated measures correlation) that accounts for non-independence among observations comprising the
entire observation period (from P2 to P6), to investigate the associations between the bacterial diversity,
abundance and predicted metabolic functions and the concentration of zonulin or calprotectin. In a third
step, mixed effects linear models were used to investigate the relationship between changes in bacterial
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diversity, abundance and metabolic function and the corresponding changes in the concentration of
zonulin and calprotectin between all time point pairs.
The compatibility of observations obtained at all stages of the analysis was considered as potential
evidence of a causal relationship between the microbiota and the markers analysed. To make this
analysis easier accessible, these data are included in summary tables (Supplementary table 5).
Diversity
The Shannon index increased signi cantly in  ve out of six time intervals associated with a signi cant
increase in zonulin (i.e. P2-P4/P5/P6, P3-P5/P6, Fig. 1A, Fig. 2A) and in four out of  ve time intervals
associated with a signi cant decline in calprotectin (P2-P5/P6, P3-P5/P6, Fig. 1B, Fig. 2A). To investigate
whether or not a relationship exists between the alpha diversity and stool zonulin/calprotectin levels, we
performed correlation analysis between four alpha-diversity indices (Shannon, Simpson, Chao1,
Evenness) and the levels of these biomarkers using repeated measures correlation. The zonulin levels did
not correlate with any of the alpha diversity indices (after FDR adjustment). In contrast, the levels of
calprotectin inversely correlated with all of the alpha diversity indices calculated (Shannon’s - r = -0.30, Q 
= 0.039; Simpson’s - r = -0.23, Q = 0.048, Chao1 - r = -0.24, Q = 0.048, Evenness - r = -0.24, Q = 0.048); of
note, the strongest correlation was found for the Shannon’s diversity (Fig. 4A).
The PCo2 scores decreased signi cantly in  ve out of the six time intervals associated with a signi cant
rise in zonulin (P2-P4/P5/P6, P3-P5/P6, Fig. 1A, Fig. 2D) and in all  ve time intervals associated with a
signi cant decrease in calprotectin (P2-P5/P6, P3-P5/P6, P4-P6, Fig. 1B, Fig. 2D). Besides, there was
some similarity between the longitudinal zonulin and PCo1 scores pattern (Fig. 1A, Fig. 2C). Therefore, we
explored the correlations between the zonulin and calprotectin levels and the per-sample positions on the
 rst two PCoA axes using repeated measures correlation analysis. We did not  nd any signi cant
correlation (zonulin and PCo1: r = 0.06, P = 0.637; zonulin and PCo2: r = -0.23, P = 0.053; calprotectin and
PCo1: r = 0.11, P = 0.363; calprotectin and PCo2: r = 0.19, P = 0.109) suggesting that the overall
compositional pro les (captured by the  rst two PCo dimensions) were not associated with the levels of
zonulin or calprotectin (Fig. 4B, C). Moreover, using likelihood ratio tests of the nested models, no
association the between Bray-Curtis distances and the changes in the zonulin levels was found (non-
interaction model: df = 1, P = 0.121, Q = 0.241; interaction model: df = 9, P = 0.965, Q = 0.965). However,
there was a signi cant association between the Bray-Curtis distances and the changes in calprotectin
levels (time period x calprotectin change interaction model: df = 9, P = 0.013, Q = 0.025). The post-hoc
tests revealed signi cant correlations between the changes in calprotectin levels and the Bray-Curtis
distances for P2-P3 and P3-P4; however, they were not signi cant after FDR adjustment (Q = 0.216 and Q 
= 0.110, respectively, Fig. 4D).
Microbiota composition and functional pro les concerning
stool zonulin and calprotectin
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Despite the lack of associations between alpha diversity and the zonulin levels as well as between beta
diversity and the levels of both biomarkers (zonulin and calprotectin) (Fig. 4), we sought to examine more
particular relationships between the levels of these permeability/in ammation-associated biomarkers
and the abundances of speci c gut bacterial taxa in the context of  ve taxonomic ranks (from genus to
phylum levels) as well as the PICRUSt2-predicted MetaCyc metabolic pathways.
Interestingly, the changes in abundance of several bacteria coincided with signi cant time dependent
changes in the levels of zonulin or calprotectin (Fig. 1, Fig. 3A). For example, there was an increase in the
abundance of Lachnoclostridium, Ruminococcus (gnavus group), Carnobacteriaceae, Lachnospiraceae,
Peptostreptococcaceae, Coriobacteriales, and a decrease of Corynebacteriales among all time points
associated with an increase in the zonulin concentration. Additionally, there was an increase in the
abundance of Anaerostipes and a decrease in the abundance of Enterococcaceae among all time points
associated with a decrease in calprotectin concentration. To investigate this further, we computed the
repeated measures correlations (encompassing the whole study period; Fig. 5 and Supplementary
Table 5) between the levels of both markers and the gut microorganisms.
In the correlations between gut microorganisms and stool calprotectin, we observed signi cant
associations at the genus level (n = 3), the family level (n = 3), and the order level (n = 1). Moreover, the
levels of zonulin were correlated with the abundance of 19 microorganisms: at the genus level (n = 5), at
the family level (n = 5), at the order level (n = 5) and the class level (n = 4) (Fig. 5A and Supplementary
Table 1). Speci cally, calprotectin correlated positively with Staphylococcus, Enterococcus,
Staphylococcacae, and Enterococcaceae and negatively with Anaerostipes, Ruminococcacea and
Clostridiales, whereas zonulin correlated positively with Lachnoclostridium, the Ruminococcus gnavus
group, the Ruminococcus torques group, Lachnospiraceae, Peptostreptococcaceae, Ruminococcacea,
Erysipelotrichales, Coriobacteriales, Clostridiales, Clostridia, Coriobacteria and negatively with
Staphylococcus, Corynebacterium, Moraxellaceae, Staphylococcaceae, Bacillales, Pseudomonadales,
Alphaproteobacteria, and Bacilli. Of note, the genus Staphylococcus, the families Ruminococcaceae and
Staphylococcaceae, and the order Clostridiales were simultaneously and oppositely correlated with both
biomarkers in the PMU cohort (Fig. 5A) and with calprotectin in the HMS cohort, exhibiting the same
direction and similar magnitudes as those in the PMU cohort (Supplementary Table 2). Additionally,
zonulin correlated signi cantly with 10 MetCyc pathways belonging to 4 superclasses (Superpathways:
FUC-RHAMCAT-PWY, Degradation/Utilization/Assimilation: FUCCAT-PWY, PWY-6353, PWY-7237,
SALVADEHYPOX-PWY, Generation of Precursor Metabolites and Energy: PWY-5676, PWY-5677, PWY-
6588, PWY-7003, and Biosynthesis: PWY-6478), of which two pathways, PWY-5677 and PWY-6588, were
the only pathways associated with calprotectin (Fig. 5B). The correlation between calprotectin and
predicted metabolic pathways from the HMS cohort revealed 15 pathways signi cantly correlating with
calprotectin levels; however, none of them overlapped with the correlations found in the PMU cohort
(Supplementary Table 2).
In order to gain more insight into the causal relationship between the microbiota and zonulin/calprotectin,
the changes in the gut community features (taxonomic composition and functional pro le) and the
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changes in the levels of zonulin or calprotectin among the time points were correlated using a linear
mixed-effects model. We did not  nd any association between changes in microbiota and changes in
markers, except for the genus Ruminococcus (torques group) which was signi cantly associated with the
changes in levels of calprotectin. Of note, while the slopes differed between time point pairs suggesting
an interaction between the time point interval and the Ruminococcus changes (e.g. a positive slope for
P2-P4 and a negative slope for P4-P5, Fig. 6B), the interaction model (LRT, df = 9, P = 0.424, Q = 0.910) did
not  t signi cantly better than the common (positive) slope model (LRT, df = 1, P = 0.002, Q = 0.015, β = 
2.94, SE = 0.81, Fig. 6A). Thus, the abundance of Ruminococcus (torques group) changes in parallel with
the changes in stool calprotectin levels regardless of time interval, thereby suggesting that both can be
causatively connected. However, this observation was not con rmed in the validation analysis and must
be taken with caution. The analysis in the context of higher taxonomic ranks for the PMU and HMS
cohorts are shown in the Supplementary Figs. 8–10.
In addition to the changes in the composition of the human gut microbiota, we also investigated whether
the changes in functional pro les of gut microbiota were linked to the dynamics of the zonulin or
calprotectin levels. Remarkable, we found that the dynamics of stool calprotectin was negatively
associated with changes in two MetaCyc metabolic pathways: pyruvate fermentation to butanoate
(CENTFERM-PWY) and the superpathway of Clostridium acetobutylicum acidogenic fermentation (PWY-
6590) (Fig. 7C, D). The common slope model was the best  t for these pathways and the regression
coe cients were β = -4.54, SE = 1.08, LRT: df = 1, P = 0.0002, Q = 0.028 and β = -4.48, SE = 1.16, LRT: df = 
1, P = 0.0002, Q = 0.026, respectively. For zonulin, the common slope model was the best  t for a change
in the pentose phosphate pathway (PENTOSE-P-PWY) only (β = 9.49, SE = 1.93, LRT: df = 1, P = 3.98e-6, Q 
= 0.001, Fig. 7A). In addition, the dynamics of zonulin was associated with changes in 3 MetaCyc
pathways: pyrimidine deoxyribonucleotides de novo biosynthesis III (PWY-6545), the superpathway of
glucose and xylose degradation (PWY-6901), and the super pathway of pyridoxal 5'-phosphate
biosynthesis and salvage (PWY0-845). For those 3 pathways, as illustrated in Fig. 7B for PWY-6545, the
models with different slopes (i.e. including an interaction between all time point pairs and pathway
changes)  tted the data signi cantly better than the common slope model. For example, the change in
zonulin levels was associated negatively with a change in PWY-6545 (LRT, df = 9, P = 4.15e-5, Q = 0.014)
between P3 and P4 (β = -8.46, SE = 2.58, P = 0.001, Q = 0.012), yet positively between P4 and P6 (β = 
12.36, SE = 4.08, P = 0.003, Q = 0.012) as well as P5 and P6 (β = 10.09, SE = 3.41, P = 0.004, Q = 0.012,
Fig. 7B). For the other two pathways, PWY-6901 (LRT, df = 9, P = 0.0005, Q = 0.046), and PWY0-845 (LRT,
df = 9, P = 0.0008, Q = 0.049), signi cant associations were found between P3 and P4 (β = 23.60, SE = 
7.35, P = 0.002, Q = 0.008) as well as P5 and P6 (β = 36.08, SE = 10.56, P = 0.0008, Q = 0.008) for PWY-
6901, and between P3 and P4 for the PWY0-845 (β = 13.07, SE = 3.66, P = 0.0005, Q = 0.005). For the full
results, see Supplementary Tables 3 and 4.
However, it should be noted that the above results (concerning calprotectin) were not con rmed in the
HMS cohort: 44 pathways showed a correlation with the dynamics of calprotectin (all under the common
slope model), but the CENTFERM-PWY (P = 0.051, Q = 0.131) and PWY-6590 (P = 0.056, Q = 0.140) did not
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(Supplementary Fig. 11). The relationships between the changes in abundance in the gut, the MetaCyc
pathways, and the changes in calprotectin levels in the HMS cohort are shown in Supplementary Fig. 12.
Discussion
This is the  rst study in which putative associations between the gut microbiota and the concentrations
of zonulin and calprotectin in children's stool during the  rst two years of life have been investigated. The
study of zonulin allows the non-invasive assessment of the functional state of the small intestinal
paracellular permeability; additionally, the calprotectin measurements provide insight into the
development of the immune system after birth. The observed results indicate that small intestinal
paracellular permeability measured based on zonulin concentration is higher in the period from the sixth
month to the second year of life than in the  rst months of life. In line with this, the concentration of
calprotectin in stool in the  rst and second years of life is lower than that in the  rst months of life; of
note, the concentration of calprotectin at six months of age does not differ signi cantly from that in the
previous or later adjacent time points. Since the validation data also revealed a difference in the
concentration of calprotectin between the  rst and sixth months of life, this allows us to de ne the 6th
month of life as the key point for forming the small intestinal barrier and for the development of
postnatal immunity. It should also be stressed that, usually, in the sixth month of life, solid food is
introduced to children’s diet, which can signi cantly impact both gut microbiota and intestinal
permeability.
Although zonulin seems to be a valuable marker of small intestinal paracellular permeability, the data in
the context of children aged two years old or younger are scarce. Tarko et al.[37] reported signi cantly
higher blood zonulin concentrations in children with gut wall defects and infected with rotaviruses.
Saleem et al.[38] observed that the blood zonulin levels were signi cantly lower in children delivered
before 28 weeks of pregnancy. The fecal zonulin concentration in children during  rst two years of life
was not reported and its role during this period is unknown. Its relationship with gut microbiota seems to
be interesting.[38] Zonulin is involved in controlling the passage of molecules weighing at least 3.5 kDa
[39] through the intestinal barrier via its reverse in uence on TJ tightness.[40, 41] After the activation of
zonula occludens (ZO) 1, zonulin controls the low-capacity “leak” type route characterized by low
selectivity.[42, 43] Interactions between zonulin and gut microbiota can be bidirectional. Bacterial and
gluten exposure was de ned as intensive triggers of zonulin release.[19, 44] Of note, the zonulin pathway
is an innate defensive mechanism of the host, able to control the gut microbiome composition via the
“ ushing out” of microorganisms by water secreted into the intestinal lumen following hydrostatic
pressure gradients.[45] High stool zonulin levels suggest that the gut barrier allows the free  ow
exchange of various particles in infants. Moreover, it is likely that the commercially available ELISAs
detect one or more members of the zonulin family that have not been discovered yet but play some
important role during the  rst two years of life.[46]
High levels of calprotectin in feces during the  rst months of life are associated with the regulation of the
development of the immune system in neonates as well as with the adaptation to new environmental
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conditions.[25] The decrease in the fecal calprotectin concentration implies that in ammatory processes
in the gut tend to decrease from the sixth month of age, which, with the accompanying increased
paracellular intestinal permeability and bacterial alpha diversity, provides evidence of immune tolerance.
Willers et al. [25] demonstrated that mice exposed to calprotectin immediately after birth induced
microbial tolerance against the  rst wave of microbial colonization; on the other hand, the same exposure
after the neonatal period was associated with pro-in ammatory responses. Our results did not fully
corroborate these observations. The intestinal permeability in the  rst month of life, as per the zonulin
concentration, is lower than that in the later period, suggesting that the possibility of antigen
translocation early after birth is limited. After the sixth month of age, the intestinal paracellular
permeability increases, but this does not increase in ammation, as per the calprotectin concentration,
which indicates the development of immune tolerance. The differences between the two studies may be
due to the fact that Willers et al. did not directly measure intestinal permeability and additionally used an
animal model that does not closely mimic the timing of human intestinal barrier development. Moreover
the role of paracellular way in translocation of bacteria and endotoxin is still the subject of debate[22],
what requires that the observed results should be interpreted with caution.
In summary, the increased production of zonulin may be caused by changes in intestinal bacteria and by
the introduction of gliadin into the diet. In contrast, the decrease in the calprotectin content in the stool
may indicate immunological tolerance development. However, it should be remembered that breast milk
is an essential source of calprotectin, which can signi cantly in uence the fecal calprotectin content.
This said the observed changes cannot be explained solely by environmental factors as zonulin
decreases in the later years of life despite the constant consumption of gliadin. Therefore, in the context
of longitudinal analyses of biomarker trajectories, we applied corrections for the time of breastfeeding
and the type of delivery to minimize the in uence of these confounders. To help resolve the mechanisms
underlying our results, we decided to analyze whether a cause-effect relationship between the microbiota
and the biomarkers would be observed. Of note, the microbial changes in the  rst two years of life are
very dynamic and depend on the mode of delivery, feeding, antibiotic treatment, and other environmental
factors.[28, 29] However, a comprehensive analysis of all factors in uencing the gut microbiota is beyond
the scope of this study, which is focused on the relationship between the microbiota and the fecal zonulin
and calprotectin content. This said the compositional and functional comparison of the PMU and HMS
cohorts' microbiota would be very interesting.
The Shannon index (more sensitive to species richness), shared 5 and 4 signi cant time intervals with
zonulin (increasing) and calprotectin (decreasing), respectively. Similar results were observed for
coordinates of the  rst two axes in the context of a principal coordinate analysis based on the Bray-Curtis
distance, one of beta-diversity measures. However, it translated only into a negative correlation between
alpha-diversity indices, the Shannon index in particular, and calprotectin. This negative correlation may be
associated with the development of immunological tolerance. The microbial colonization of the intestine
after birth will generate a diversity of new antigens that will play an important role in the stimulating of
epithelial function and the establishing the offspring’s immune system.[47] Of note, weaning (the average
breastfeeding time in our study was about 30 weeks), and the resulting loss of milk-borne calprotectin,
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sIgA and other anti-microbial factors, along with the transition from mothers’ milk to a complex diet
(including solid food), can have a major impact on the dynamic microbiota development, and thus in the
resulting immune responses during the neonatal period.[6]
Willers et al. [25] reported that the gut microbiota's overall diversity signi cantly increases during the  rst
year of life, similarly to what we observed in this study. Moreover, they observed the increased abundance
of the bacterial classes Actinobacteria, Bacteroidia [48–50] and Clostridia, along with the decreased
abundance of Bacilli and Gammaproteobacteria over the same time period. Of note, Willers et al.[25]
demonstrated that during infancy, high abundance of Actinobacteria and low abundance of
Gammaproteobacteria are linked to high fecal calprotectin levels; additionally, at the family level, fecal
calprotectin promoted the higher abundance of Bi dobacteriaceae and the reduction of
Enterobacteriaceae via the production of acetate[51]. Taxonomic composition observed by Willers et al.
[25] might be linked to the elevation in the synthesis and reduction in the degradation of short-chain fatty
acids (SCFAs) and therefore leading to the overrepresentation of health-promoting gut microbiota
metabolic functions. Our results con rm the observations obtained by Willers et al.[25] in terms of
abundance; however, the correlations in the cited study were not reproduced here. Importantly, the
observed differences may depend on the difference between the investigated populations (Polish and
German) or/and the analytical methods used. This said the analysis of both data-sets showed
similarities with respect to the correlation between the levels of calprotectin and bacteria at the family
level.
Interestingly, the bacteria associated with zonulin and calprotectin (Supplementary Table 5) may be
involved in the production of SCFA, which is a protective factor in the context of intestinal barrier integrity
and of in ammatory processes. Particularly, the different taxonomic groups of bacteria within the class
Clostridia were associated with increased zonulin and decreased calprotectin concentrations. Within this
class, the family Ruminococcaceae was more abundant in women with low zonulin concentrations in a
previous study; however, here, we observed the opposite pattern. Importantly, not all bacteria within this
class have the same properties. For instance, the genus Ruminococcus (gnavus group) – positively
correlated with fecal zonulin concentration, is increased in patients with IBS-D and Crohn’s disease, which
suggests its pro-in ammatory activity. An interesting result was obtained in the case of the
Ruminococcus (torques group). Ruminococcus torques, a butyrate producer, have been found to
dominate patients' gut milieu with Crohn’s Disease.[52, 53] They were also studied in the context of
individuals with increased risk of upper gastrointestinal tract involvement, but with inconclusive results.
[54–56] Importantly, Ruminococcus torques are able to utilize mucin in the human intestine, sustaining
their adaptability to the human intestinal environment.[53, 57, 58] Consequently, increased mucin
degradation makes luminal antigens cross the gut barrier and stimulate the immune system, leading to
intestinal disorders.[59] Of note, in this study, the abundance of these above bacteria positively correlated
with the concentration zonulin and the dynamics of calprotectin concentration. Therefore, bacteria from
the Ruminococcus (torques group) may include species associated with small intestinal permeability and
immune responses in the  rst two years of life. For deeper species resolution and assessment of the gut
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functional potential future shotgun metagenomics, metabolomics, and immune analyses will be
essential.
In this study, the Bacilli class correlated with decreased zonulin and increased calprotectin levels. In
general, this class is considered bene cial for gut health, which is in line with decreased zonulin levels.
On the other hand, the family Staphylococcaceae and genus Staphylococcus from the Bacilli class are
the most prominent bacteria in human milk, an important calprotectin source in the infant. Family
Enterococcaceae belongs to opportunistic pathogens, considered as potential marker for IBD what can
explain correlation with increased fecal calprotectin concentration. However, our present results do not
allow consistent conclusions on the role of bacteria in the small intestinal barrier's permeability or the
immune system in the  rst two years of life. For example, the Lachnoclostridium genus produces SCFAs
and occurs in lower amounts in patients with gastrointestinal cancers; therefore, in theory, it should
decrease intestinal permeability; however, it was correlated with increased concentrations of zonulin in
the neonatal stool in this study. Alphaproteobacteria occur in high numbers in patients with IBD and are
negatively associated with the concentration of zonulin. The order Corynebacteriales is associated with
decreased zonulin and belongs to the class Actinobacteria, which was positively correlated with
calprotectin in the study by Willers et al.[25] The order Pseudomonadales and the family Moraxellaceae
are negatively correlated with zonulin and belong to Gammaproteobacteria, negatively correlated with
calprotectin in the study by Willers et al. Therefore, in no case was there a full consistency of microbiota
changes between particular time points and changes in the levels of zonulin and/or calprotectin. This
said the validation analysis suggested that the genus Staphylococcus and the family Staphylococcaceae
(positively correlated with the concentration of calprotectin), as well as the family Ruminococcaceae and
the order Clostridiales (negatively correlated with the concentration of calprotectin), are potential
candidates as markers of the development of the immune system in children under two years of age.
Finally, we analyzed the metabolic pathways linked with bacterial abundance (Supplementary Table 6).
We were able to show that the pathways involved in the production of SCFAs and the metabolism of
carbohydrates were positively associated with fecal zonulin and negatively with calprotectin. The latter
association suggests the role of SCFA in the immune response. However, the positive associations and
correlations between pathways involved in SCFA production and the zonulin elevation are di cult to
explain, suggesting that other mechanisms are also involved in regulating small intestinal barrier
permeability in children of up to two years old. It should be emphasized that the variations in the
concentrations of zonulin and calprotectin overlapped with the introduction of new foods to the child’s
diet around the sixth month of life (addition of soup, grated apple), with the consequent alteration in the
gut microbiota composition and the related metabolic functions. For example, metabolic pathways
involved in the metabolism of carbohydrates, vitamin B6 and nucleotides positively correlated with the
levels of zonulin, which could suggest that an “open” small intestinal paracellular permeability could play
a role in the transportation of metabolic reaction products during intensive growth and development.
However, the paracellular transport of nutrients is known to play a rather minor role. The observed results
support the concept that paracellular permeability is only the component of intestinal barrier[22] and that
SCFAs affect mostly transcellular route via metabolism of enterocytes. Of note, the analysis of the
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validation data did not con rm our observations concerning the metabolic pathways. Therefore, shotgun
sequencing and metabolomic analyses should be performed to shed more light on these processes.
Our study is not without limitations. Our cohort was relatively small, though enough to observe changes
in zonulin and calprotectin levels as well as in gut microbiota composition during the  rst two years of
life with appropriate power. Of note, our results were validated using the HMS cohort as well as via the
comparison between the microbiota of meconium and stool samples collected at other time points.
Moreover, our samples were somewhat heterogeneous (with respect to the delivery mode, the use of
antibiotics, nutrition, and other environmental factors). Of note, all of these factors can affect the gut
microbiota; however, in term infants, the mode of delivery seems to impact fecal calprotectin levels only
in the  rst week of life.[25] Moreover, in our study, we did not use direct methods to measure the gut
permeability; we used biomarkers, for which data in healthy children < two years old are limited. In fact,
there are studies reported on the fecal levels of zonulin in adults but not in children. It is known that in
children, the levels of zonulin and calprotectin are incomparably higher than those in adults, changing
over time, and could be in uenced by e.g., breastfeeding, the dietary patterns, the mode of delivery, and
the consumption of gliadin. In the current study, however, due to the small sample size, we did not
analyze these biomarkers separately in the context of different delivery modes. Also, we did not collect
detailed data on antibiotic exposure. Further, we did not measure these factors in blood (ethical reason -
healthy children); only in stool. Moreover, since no metabolomic, immunological, or shotgun
metagenomic analyses were performed, the results we obtained must be treated with caution.
Mechanistic studies are still needed to investigate the relationship between microbiota and gut
permeability and the immune system.
Conclusions
Overall, based on the results, we can conclude that the gut microbiota composition, the small intestinal
paracellular permeability, as well as immune system-related markers change dynamically during the  rst
two years of life. Although the gut microbiota composition and the related metabolic functions were
correlated with zonulin and calprotectin levels, neither clear causation nor obvious health consequences
can be proven in this study. However, our data may suggest that the Ruminococcus (torques group) might
be more involved in controlling paracellular permeability during the  rst two years of life than previously
considered. Additionally, our data indicate that the genus Staphylococcus and the family
Staphylococcaceae (positively correlated with the fecal calprotectin concentration) and the family
Ruminococcaceae, as well as the order Clostridiales (negatively correlated with the fecal calprotectin
concentration), may be potential biomarkers of the development of the immune system development or
in ammatory reactions in children younger than two years old. It must be emphasized that further
longitudinal studies are required to investigate the mechanism behind gut permeability in children and its
in uence on health. The establishment of gut permeability markers optimal for children as well as of
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